- Home
- AGMH vs GRI Comparison
AGMH vs GRI Comparison
Compare AGMH & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- GRI
- Stock Information
- Founded
- AGMH 2015
- GRI 2018
- Country
- AGMH Hong Kong
- GRI United States
- Employees
- AGMH N/A
- GRI N/A
- Industry
- AGMH EDP Services
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- GRI Health Care
- Exchange
- AGMH Nasdaq
- GRI Nasdaq
- Market Cap
- AGMH 3.5M
- GRI 3.4M
- IPO Year
- AGMH 2018
- GRI N/A
- Fundamental
- Price
- AGMH $2.84
- GRI $1.65
- Analyst Decision
- AGMH
- GRI Strong Buy
- Analyst Count
- AGMH 0
- GRI 2
- Target Price
- AGMH N/A
- GRI $22.00
- AVG Volume (30 Days)
- AGMH 616.9K
- GRI 136.5K
- Earning Date
- AGMH 07-22-2025
- GRI 08-13-2025
- Dividend Yield
- AGMH N/A
- GRI N/A
- EPS Growth
- AGMH N/A
- GRI N/A
- EPS
- AGMH 6.43
- GRI N/A
- Revenue
- AGMH $32,044,575.00
- GRI N/A
- Revenue This Year
- AGMH N/A
- GRI N/A
- Revenue Next Year
- AGMH N/A
- GRI N/A
- P/E Ratio
- AGMH $0.42
- GRI N/A
- Revenue Growth
- AGMH N/A
- GRI N/A
- 52 Week Low
- AGMH $1.09
- GRI $1.10
- 52 Week High
- AGMH $109.50
- GRI $43.69
- Technical
- Relative Strength Index (RSI)
- AGMH 53.64
- GRI 57.27
- Support Level
- AGMH $2.40
- GRI $1.39
- Resistance Level
- AGMH $3.10
- GRI $1.45
- Average True Range (ATR)
- AGMH 0.30
- GRI 0.12
- MACD
- AGMH 0.12
- GRI 0.05
- Stochastic Oscillator
- AGMH 85.58
- GRI 69.79
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.